Amgen slides 10% amid olpasiran read

Amgen's stock price fell 10% on Tuesday after a late-stage cardiovascular trial failure at Novartis raised concerns about the outlook for Amgen's own olpasiran program.

• Amgen's stock price dropped 10% on Tuesday.
• The decline was due to concerns about the olpasiran program.
• A late-stage cardiovascular trial failure at Novartis raised concerns.
• The stock closed at $393.17, down $44.06 from its prior close.
• Trading volume was nearly three times the one-month average.

The stock closed at $393.17, down $44.06 from its prior close, on volume nearly three times its one-month average.